AbCellera Biologics Inc. (ABCL) Stock Research
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Latest price: 13.92 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Hayden Michael R | buy | 2026-08-24 | 570442.32 |
| Montalbano John S. | buy | 2026-08-18 | 110300 |
| Hayden Michael R | buy | 2026-08-12 | 481033.19 |
| Booth Andrew | buy | 2026-08-14 | 383904 |
| Montalbano John S. | buy | 2026-05-14 | 95400 |
| Thermopylae Holdings Ltd. | buy | 2026-02-27 | 130720 |
| Thermopylae Holdings Ltd. | buy | 2026-02-26 | 580284.39 |
| Booth Andrew | buy | 2026-02-27 | 145692 |
| Montalbano John S. | buy | 2025-11-26 | 178460 |
| Thermopylae Holdings Ltd. | buy | 2025-03-11 | 742242.96 |